{"product_id":"sdbiosensor-swot-analysis","title":"SD BioSensor SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSD Biosensor’s SWOT highlights robust diagnostic tech and strong regulatory footholds, balanced against competitive pressures and supply-chain sensitivity; growth hinges on R\u0026amp;D and expanded clinical partnerships. Discover the full strategic picture—purchase the complete SWOT analysis for a professionally written, editable report and Excel tools to guide investment, planning, and pitch-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Global Rapid Test Market Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSD Biosensor holds a leading share of the global rapid diagnostic test market, producing over 300 million rapid tests annually by Q4 2025 and serving 120+ countries, which supports scale-driven unit costs roughly 25–35% below regional peers.\u003c\/p\u003e\n\u003cp\u003eHigh-volume manufacturing and automated lines helped sustain gross margins near 40% in FY2024–2025, enabling competitive pricing while preserving profitability versus smaller rivals lacking similar capacity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic US Market Entry via Meridian Bioscience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Meridian Bioscience acquisition gave SD Biosensor a direct US foothold and a 2024 pro forma revenue uplift of about $180m, shifting it from export-only to significant domestic sales in the world’s largest healthcare market (US healthcare spending ~$4.6trn in 2023).\u003c\/p\u003e\n\u003cp\u003eMeridian’s mature US distribution network and 3,700+ customer accounts broaden SD Biosensor’s reach and cut average delivery lead times, supporting cross-sell into its core diagnostics lines.\u003c\/p\u003e\n\u003cp\u003eMeridian adds a complementary life-science portfolio—molecular reagents and immunoassays—diversifying SD Biosensor beyond point-of-care tests and improving gross margin mix by an estimated 150–300 bps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust R\u0026amp;D and Manufacturing Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSD Biosensor’s vertical integration—covering raw materials to final assembly—cuts lead times and enabled a 37% faster prototype-to-production cycle in 2024, supporting rapid rollouts during outbreaks; their integrated plants scaled antigen test output to 120 million units in 2024 while holding defect rates under 0.4%, sustaining high quality as a point-of-care edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Diagnostic Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSD Biosensor expanded beyond rapid kits into immunoassay, molecular diagnostics, and blood glucose systems, lowering reliance on one product line and serving hospitals to small clinics.\u003c\/p\u003e\n\u003cp\u003eThe move into chronic disease tools (glucose monitors) adds recurring sales; in 2024 diagnostics sales mix shifted ~30% chronic vs 70% infectious, stabilizing revenue after 2020 peaks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiversified product mix: rapid, immunoassay, molecular, glucose\u003c\/li\u003e\n\u003cli\u003eCustomer reach: tertiary hospitals to clinics\u003c\/li\u003e\n\u003cli\u003e2024 mix: ~30% chronic, ~70% infectious\u003c\/li\u003e\n\u003cli\u003eMore stable recurring revenue, lower single-category risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Cash Position and Financial Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSD Biosensor built reserves during the 2020–2022 pandemic, leaving cash and short-term investments of about $420M at end-2025, giving a strong war chest for R\u0026amp;D and strategic buys.\u003c\/p\u003e\n\u003cp\u003eThis liquidity lets the company absorb market swings, pursue bolt-on M\u0026amp;A without heavy debt, and fund multi-year growth projects in a cyclical diagnostics market.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$420M cash\/short-term investments (end-2025)\u003c\/li\u003e\n\u003cli\u003eNet debt ~zero (end-2025)\u003c\/li\u003e\n\u003cli\u003eCapacity for aggressive M\u0026amp;A and R\u0026amp;D funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal rapid-test leader: 300M+ units, ~40% margins, $420M cash, $180M Meridian boost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket leader with 300M+ rapid tests\/year (Q4 2025), 120+ countries; scale cuts unit costs 25–35% vs peers. FY2024–25 gross margins ~40%; cash\/short-term investments $420M (end-2025), net debt ~0. Meridian acquisition added $180M pro forma 2024 revenue and 3,700+ US accounts; vertical integration cut prototype-to-production time 37% and defect rates \u0026lt;0.4%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual rapid tests\u003c\/td\u003e\n\u003ctd\u003e300M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMeridian uplift\u003c\/td\u003e\n\u003ctd\u003e$180M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of SD BioSensor, highlighting its technological strengths and market positioning, outlining operational weaknesses, identifying growth opportunities in diagnostics and partnerships, and assessing external threats such as regulatory changes and competitive pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT matrix for SD Biosensor that speeds strategic alignment and stakeholder briefings with clean, editable formatting for rapid updates and presentation-ready snapshots.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Pandemic Revenue Normalization Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSD Biosensor struggled to replace COVID-19 peak revenues (~KRW 1.2 trillion in 2021) with recurring diagnostics sales; 2024 revenue fell ~48% from peak to KRW 630 billion, showing normalization pressures.\u003c\/p\u003e\n\u003cp\u003eDiversification into chronic-disease and POCT products is ongoing, but inconsistent quarterly growth and a 35% drop in market cap since 2021 have strained investor sentiment.\u003c\/p\u003e\n\u003cp\u003eManagement must balance legacy rapid-scale operations with a smaller, stabilized diagnostics market and target 10–15% annual organic growth to reassure stakeholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration Risks with International Subsidiaries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpmanaging a global footprint after the meridian bioscience acquisition valued at about raises cultural and operational integration risks across countries increasing hr governance friction. disparities in corporate legacy it stacks local regulatory regimes have past integrations driven higher sg per revenue dollar. overseeing international manufacturing sites heightens supply-chain bottleneck risk can cause quality variance shown by uptick batch rejections comparable deals.\u003e\n\u003c\/pmanaging\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLower Brand Equity in High-End Molecular Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpwhile sd biosensor leads rapid testing with global covid antigen sales exceeding in its brand equity high-end molecular diagnostics lags behind roche and danaher which control of centralized reagent revenue\u003e\n\u003cpestablishing the m10 as a clinical gold standard will need multi-year costly efforts: phased marketing payer engagement and large validation studies programs cost take years.\u003e\n\u003cpovercoming incumbent advantage in premium hospitals is slow and capital-intensive western incumbents entrenched procurement relationships service contracts often keep customer acquisition costs higher for new entrants.\u003e\n\u003c\/povercoming\u003e\u003c\/pestablishing\u003e\u003c\/pwhile\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Revenue Concentration in Specific Regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite global operations, roughly 62% of SD Biosensor’s 2024 revenue came from South Korea and nearby Asian markets, leaving the firm vulnerable to local recessions, shifts in Korean\/National Health Insurance reimbursement, or regional geopolitical strains.\u003c\/p\u003e\n\u003cp\u003eManagement is shifting sales toward North America and Europe, but moving from 38% to a balanced split involves regulatory, distribution, and market-build execution risks that could pressure margins and growth timing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue concentration ~62% Asia\u003c\/li\u003e\n\u003cli\u003eReimbursement policy risk: Korean NHI updates in 2023–24\u003c\/li\u003e\n\u003cli\u003eGoal: raise NA\/EU share from ~38%—execution risk\u003c\/li\u003e\n\u003cli\u003eGeopolitical exposure: regional trade tensions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMargin Compression in Commodity Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMargin compression is intensifying as the rapid diagnostic test (RDT) market commoditizes; global RDT revenues grew 6% in 2024 but average selling prices fell ~8% year-on-year, squeezing margins for standard lateral-flow assays.\u003c\/p\u003e\n\u003cp\u003eRegional low-cost entrants in Asia and Africa now undercut prices by 20–40%, forcing SD Biosensor to invest more in R\u0026amp;D and digital integration to sustain a premium.\u003c\/p\u003e\n\u003cp\u003eWithout clear tech or digital differentiation—e.g., connected readers, data services—SD Biosensor risks a pricing race to the bottom and lower EBITDA margins versus 2023 levels (reported EBITDA margin ~12%).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 ASP decline ~8%\u003c\/li\u003e\n\u003cli\u003eRegional undercutting 20–40%\u003c\/li\u003e\n\u003cli\u003e2023 EBITDA margin ~12%\u003c\/li\u003e\n\u003cli\u003eNeed investment in R\u0026amp;D\/digital to avoid commoditization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue halved to KRW630B, Meridian deal raises costs as ASPs drop and rivals undercut\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue collapsed from KRW 1.2T (2021) to KRW 630B (2024), showing weak post-COVID recurring sales and 35% market-cap decline; 62% revenue still tied to Asia. Integration of Meridian Bioscience (~$350M deal, 2024) raises 8–12% higher SG\u0026amp;A and supply risks; ASPs fell ~8% in 2024 while regional rivals undercut 20–40%, pressuring a 2023 EBITDA margin ~12%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak rev (2021)\u003c\/td\u003e\n\u003ctd\u003eKRW 1.2T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRev (2024)\u003c\/td\u003e\n\u003ctd\u003eKRW 630B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsia revenue share (2024)\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMeridian deal\u003c\/td\u003e\n\u003ctd\u003e~$350M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASP change (2024)\u003c\/td\u003e\n\u003ctd\u003e−8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA margin (2023)\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSD BioSensor SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752734470521,"sku":"sdbiosensor-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sdbiosensor-swot-analysis.png?v=1772244586","url":"https:\/\/matrixbcg.com\/products\/sdbiosensor-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}